Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

International Journal of Women's Health

Volumn 6, Issue 1, 2014, Pages 351-358

  Luyckx, Mathieu ^a   Votino, Raffaella ^a   Squifflet, Jean Luc ^a   Baurain, Jean François ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chemotherapy; Folate receptor; Platinum resistant ovarian cancer

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID; PLATINUM COMPLEX; VINTAFOLIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CELL SURFACE; CONSTIPATION; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; ENDOCYTOSIS; FATIGUE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTEMIC THERAPY; TISSUE DISTRIBUTION; VOMITING;

EID: 84897372062     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/IJWH.S39696     Document Type: Article

References (54)

1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed February 19, 2014.
2. Ovarian cancer [webpage on the Internet]. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/ovary.html. Accessed February 7, 2014.
3. Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21(2):75-80.
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
5. Katsumata N, Yasuda M, Takahashi F, et al; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
6. Vergote I, Tropé CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
7. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian cancer (EOC)? Gynecol Oncol. 2006;103:559-564.
8. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578-592.
9. Ulrich CM. Folate and cancer prevention - where to next? Counterpoint. Cancer Epidemiol Biomarkers Prev. 2008;17:2226-2230.
10. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm. 2003;66:403-456.
11. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007;26:111-128.
12. Antony AC. Folate receptors. Annu Rev Nutr. 1996;16:501-521.
13. Leamon CP, Low PS. Delivery of macromolecules into living cells: a methods that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88:5572-5576.
14. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
15. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescence conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol. 2004;287:C517-C526.
16. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol. 1992;44(9):1898-1901.
17. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994;33(5):1209-1215.
18. Crane LM, Arts HJ, van Oosten M, et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr). 2012;35:9-18.
19. Wu M, Gunning W, Ratman M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999;8:775-782.
20. Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6:360-369.
21. Despierre E, Lambrechts S, Leunen K, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian cancer and endometrial cancer after chemotherapy. Gynecol Oncol. 2013;130:192-199.
22. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3): 619-626.
23. Siu MK, Kong DS, Chan HY, et al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcomes. PLoS One. 2012;7(11):e47201.
24. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2): 121-126.
25. Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. Int J Gynecol Cancer. 2012;22(8):1337-1343.
26. Guo WJ, Zhang YM, Zhang L, et al. Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin. Autophagy. 2013;9:996-1008.
27. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. Epub September 8, 2013.
28. Mironava T, Simon M, Rafailovich MH, Rigas B. Platinum folate nanoparticles toxicity: cancer vs normal cells. Toxicol In Vitro. 2013;27:882-889.
29. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-393.
30. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990;2:35-43.
31. Ottone F, Miotti S, Bottini C, et al. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer. 1997;76(1):77-82.
32. Tazi Y, Pautier P, Leary A, Lhomme C. [Chemotherapy in epithelial ovarian cancer]. Gynecol Obstet Fertil. 2013;41(10):611-616. French.
33. Leamon CP, Lovejoy CD, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med. 2013;6:113-125.
34. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013;131:493-498.
35. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett. 2006;16(19):5093-5096.
36. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007;67: 4434-4442.
37. Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012;30:4011-4016.
38. Leamon CP, Reddy JA, Klein PJ, et al. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther. 2011;336:336-343.
39. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31(35):4400-4406.
40. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397-1412.
41. Pujade-Lauraine E, Hilpert F, Weber B, et al; AURELIA Investigators. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). ASCO Annual Meeting 2012, Chicago, Illinois, USA, Saturday 2 June 2012. J Clin Oncol. 2012;30(Suppl 18):abstract LBA5002.
42. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
43. Spannuth W, Lyn Y, Merritt W, et al. Therapeutic efficacy of folate receptor α blockade with MORAb-003 in ovarian cancer. Gynecol Oncol. 2008;108:135 (abstract 307).
44. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288-5295.
45. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129: 452-458.
46. PR Newswire. Morphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer [press release]. Exton, PA: Morphotek® Inc., 2010 [March 12]. Available from: http://www.prnewswire.com/news-releases/morphotek-announces-top-line-results-of-a-phase-iii-study-of-farletuzumab-in-patients-with-relapsed-platinum-sensitive-epithelial-ovarian-cancer-186384621.html. Accessed February 20, 2014.
47. Esai Co., Ltd. Eisai announces results of phase III study of anticancer agent farletuzumab in patients with relapsed platinum-sensitive ovarian cancer [press release]. Tokyo, Japen: Esai Co., Ltd.; 2013 [January 11]. Available from: http://www.eisai.com/news/news201305.html. Accessed February 20, 2014.
48. Merck Sharp and Dohme Corp. A randomized double-blind phase 3 trial comparing EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01170650. NLMidentifier: NCT01170650. Accessed.
49. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancer. Int J Cancer. 1997;74:193-198.
50. Bagnoli M, Canevari S, Figini M, et al. A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol. 2003;88:S140-S144.
51. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338: 284-293.
52. Kelemen LE, Sellers TA, Keeney GL, Lingle WL. Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2168-2172.
53. O'Shannessy DJ, Somers EB, Smale R, Fu YS. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol. 2013;32(3):256-268.
54. Leamon CP, Reddy JA, Haines B, Dussault I. Vintafolide: a first-in-class small molecule drug conjugate targeting folate receptor-positive tumors. Poster #5502/12.